Comparative study of portal vein stent and TACE combined therapy with or without endovascular implantation of iodine-125 seeds strand for treating patients with hepatocellular carcinoma and main portal vein tumor thrombus.
- VernacularTitle:门静脉支架及经动脉药物治疗栓塞联合或未联合血管内植入碘-125粒子条治疗肝癌合并门静脉主干癌栓的比较
- Author:
Lin-lin WU
1
;
Jian-jun LUO
;
Zhi-ping YAN
;
Jian-hua WANG
;
Xiao-lin WANG
;
Xue-bin ZHANG
;
Zhu-ting FANG
;
Wen ZHANG
Author Information
- Publication Type:Journal Article
- MeSH: Carcinoma, Hepatocellular; complications; therapy; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Humans; Iodine Radioisotopes; administration & dosage; therapeutic use; Liver Neoplasms; therapy; Male; Middle Aged; Neoplastic Cells, Circulating; Portal Vein; physiopathology; surgery; Retrospective Studies; Stents; Treatment Outcome; Venous Thrombosis; complications; therapy
- From: Chinese Journal of Hepatology 2012;20(12):915-919
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo compare the efficacies of portal vein stenting and transcatheter arterial chemoembolization (TACE) combined therapy performed with or without endovascular implantation of iodine-125 (125I) seeds strand in patients with hepatocellular carcinoma (HCC) and main portal vein tumor thrombus (MPVTT).
METHODSOne-hundred-and-six patients with HCC complicated by MPVTT who were treated with portal vein stents and TACE, either with (Group A, n=56) or without (Group B, n=50) endovascular implantation of 125I seeds strand, between July 2005 and April 2011, were retrospectively analyzed. Overall survival, stent patency, and procedure-related adverse events were compared between the two groups.
RESULTSThe technical success rate was 100% for placement of 125I seeds strands and stents in the obstructed main portal vein. No serious procedure-related adverse events were recorded. Group A had significantly higher median survival (335 days vs. group B: 146 days; P=0.001, hazard ratio (HR)=2.244). Additionally, group A had significantly higher median stent patency (400 days vs. group B: 190 days; P=0.005, HR=2.479).
CONCLUSIONThe combination therapeutic strategy of portal vein stenting and TACE with endovascular implantation of 125I seeds strands improves the survival of HCC patients with MPVTT complication.
